Ruthenium(II) Arene Compounds as Versatile Anticancer Agents

Ruthenium-based compounds are an attractive alternative to clinically used platinum drugs due to several features including a wide range of accessible oxidation states, varied synthetic chemistry and typically lower general toxicities. One series of ruthenium(II)-arene-pta, RAPTA (pta = 1,3,5-triaza-7-phosphatricyclo[3.3.1.1] decane) compounds has been found to show particularly high selectivity towards cancer cells in both in vitro and in vivo studies.


Published in:
Chimia, 63, 217-219
Year:
2009
Keywords:
Laboratories:




 Record created 2010-11-30, last modified 2018-03-17


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)